Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti–Interleukin 10 Receptor Antibody by Vicari, Alain P. et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/08/541/9 $5.00
Volume 196, Number 4, August 19, 2002 541–549
http://www.jem.org/cgi/doi/10.1084/jem.20020732
 
541
 
Reversal of Tumor-induced Dendritic Cell Paralysis by CpG 
Immunostimulatory Oligonucleotide and Anti–Interleukin 10 
Receptor Antibody
 
Alain P. Vicari,
 
1
 
 Claudia Chiodoni,
 
2
 
 Céline Vaure,
 
1
 
 Smina Aït-Yahia,
 
1
 
Christophe Dercamp,
 
1
 
 Fabien Matsos,
 
1
 
 Olivier Reynard,
 
1
 
Catherine Taverne,
 
1
 
 Philippe Merle,
 
3
 
 Mario P. Colombo,
 
2
 
Anne O’Garra,
 
4
 
 Giorgio Trinchieri,
 
1
 
 and Christophe Caux
 
1
 
1
 
Schering-Plough Laboratory for Immunological Research, 69571 Dardilly, France
 
2
 
Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milano, Italy
 
3
 
Institut National de la Sante et de la Recherche Medicale U271, 69424 Lyon, France
 
4
 
DNAX Research Institute, Palo Alto, CA 94304
 
Abstract
 
Progressing tumors in man and mouse are often infiltrated by dendritic cells (DCs). Deficient
antitumor immunity could be related to a lack of tumor-associated antigen (TAA) presentation
by tumor-infiltrating DCs (TIDCs) or to a functional defect of TIDCs. Here we investigated
the phenotype and function of TIDCs in transplantable and transgenic mouse tumor models.
Although TIDCs could encompass various known DC subsets, most had an immature phenotype.
We observed that TIDCs were able to present TAA in the context of major histocompatibility
complex class I but that they were refractory to stimulation with the combination of li-
popolysaccharide, interferon 
 
 
 
, and anti-CD40 antibody. We could revert TIDC paralysis,
however, by in vitro or in vivo stimulation with the combination of a CpG immunostimulatory
sequence and an anti-interleukin 10 receptor (IL-10R) antibody. CpG or anti–IL-10R alone
were inactive in TIDCs, whereas CpG triggered activation in normal DCs. In particular,
CpG plus anti–IL-10R enhanced the TAA-specific immune response and triggered de novo
IL-12 production. Subsequently, CpG plus anti–IL-10R treatment showed robust antitumor
therapeutic activity exceeding by far that of CpG alone, and elicited antitumor immune memory.
Key words: cancer • immunosuppression • immunotherapy • interleukin 12 • Toll-like receptor
 
Introduction
 
Although the main function of dendritic cells (DCs)
 
*
 
 is
probably to orchestrate a defense against pathogens, DCs
are also well equipped to initiate antitumor responses (1).
Indeed, in vitro–generated DCs are able to sample and
present tumor antigens for the priming of cytotoxic T cells
(2) and DCs can produce the cytokines IL-12, TNF
 
 
 
,
and IFN-
 
  
 
that play diverse roles in antitumor immune
responses (1). Accordingly, several investigators have
successfully harnessed this biological potential of DCs by
preventing or curing transplantable tumors in mice after
the infusion of ex vivo–derived DCs pulsed with tumor-
associated antigens (TAAs; references 3 and 4). Today,
this strategy is being evaluated in clinical trials investigating
what is the most efficient subset of DCs, form of antigen,
and activation stimulus (5).
Although solid human tumors are frequently infiltrated
by DCs (6–8), only a few studies focused on the therapeutic
potential of tumor-infiltrating DCs (TIDCs). Yet, in a
mouse model, TIDCs were shown to have captured and
processed TAA exogenously in the MHC class I pathway
(9), suggesting that this first step toward immune reactivity
was not impaired. However, the tumor milieu appears to
lack the expression of DC activation factors such as microbial
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stimuli which are known to be crucial in DC physiology
(10). Furthermore, tumor cells or tumor-infiltrating cells
may produce IL-10, PGE
 
2
 
, and TGF
 
  
 
that impair DC func-
tions (11, 12). Thus, lack of activation in conjunction with
inhibition of DCs within tumors could explain why the im-
mune response against the tumor is not taking place. There-
fore, manipulations aimed at restoring TIDC function may
provide novel immunotherapeutic strategies against cancer.
In this report, we observed that TIDCs in several trans-
plantable and transgenic mouse tumor models uniformly had
an immature phenotype and were refractory to activation
with a combination of microbial and T cell–derived stimuli:
LPS, IFN-
 
 
 
, and anti-CD40 agonist antibody. We then
identified conditions that reverted tumor-induced DC paral-
ysis, namely the combination of an immunostimulatory un-
methylated CpG oligonucleotide and an anti–IL-10 receptor
(IL-10R) antibody. Consequently, the CpG plus anti–IL-
10R combination showed robust anti-tumor therapeutic ef-
ficacy, exceeding by far that of CpG alone.
 
Materials and Methods
 
Mice.
 
Female BALB/c, C57BL/6, and BALB/c 
 
 
 
 C57BL/6
F1 mice were from Charles River Laboratories. The X/myc
transgenic mouse lineage spontaneously develop Hepadnavirus-
related hepatocellular carcinoma due to up-regulation of c-myc
oncogene in the liver (13). Procedures involving animals and
their care were conducted in conformity with EEC Council Di-
rective 86/609, OJL 358,1, December 12, 1987.
 
DC Preparation and Culture.
 
TIDCs or lymph node DCs
were purified using CD11c
 
 
 
 Microbeads (MiniMacs; Miltenyi
Biotec) as described previously (14). DCs were purified from tu-
mors of an average of 0.5 to 0.8 cm in diameter, and the time
needed to reach such size varied from 2–4 wk depending on the
tumor model. Bone marrow–derived DCs (BM-DCs) were ob-
tained as described (14). When indicated, DCs were activated
with combinations of 10 ng/ml LPS (Sigma-Aldrich), 20 ng/ml
IFN-
 
 
 
 (R&D Systems), 20 
 
 
 
g/ml purified anti-CD40 antibody
(clone FKG45.5, a gift from A.G. Rolink, Basel Institute for Im-
munology, Basel, Switzerland), 10 
 
 
 
g/ml purified anti–IL-10R
antibody (clone 1B1.3a [15]) or control rat IgG1 antibody (clone
GL113) and 5 
 
 
 
g/ml phosphothioate-modified CpG 1668 (5
 
 
 
-
TCCATGACGTTCCTGATGCT-3
 
 
 
; MWG-Biotech), or con-
trol GpG 1668 (5
 
 
 
-TCCATGAGGTTCCTGATGCT-3
 
 
 
). In
some experiments, a 48 h supernatant made from excised 0.5 to
0.8 cm in diameter C26 tumors was added at 10% vol/vol.
 
Tumors and In Vivo Procedures.
 
The C26 colon carcinoma
(H-2
 
d
 
) and its variant C26–6CK, engineered to express the mu-
rine chemokine CCL21/SLC/6Ckine, have been described pre-
viously (14). The P815 mastocytoma (H-2
 
d
 
), LL2 lewis lung car-
cinoma and B16F0 melanoma (both H-2
 
b
 
) were purchased from
American Type Culture Collection. TSA is a H-2
 
d
 
 mammary
carcinoma (16) and MC38 a H-2
 
b
 
 colon carcinoma (17). Tumor
cells were injected subcutaneously at day 1 and tumor growth
was monitored by palpation and measurement using a caliper
three times a week. For treatment, mice were injected at day 7,
14, and 21 with various combinations of intraperitoneal 250 
 
 
 
g
anti–IL-10R antibody or control antibody and intra- or peritu-
moral 5 
 
 
 
g CpG 1668 or control GpG 1668. For cell depletion
in vivo, 0.5 mg of anti-CD8 or anti-CD4 (clones 2.43 and GK-
1.5; American Type Culture Collection) purified antibodies or 10
 
 
 
l of rabbit anti-Asialo-GM1 serum (Wako Pure Chemical In-
dustries) were injected twice a week intraperitoneally starting 1 d
prior to tumor cell inoculation, then at day 3 and once a week af-
ter the first week during the course of the treatment.
 
Flow Cytometry Analyses.
 
Fc receptors were blocked using
Fc-Block™ (BD Biosciences). The antibodies (all from BD Bio-
sciences) used in this study were: CD8
 
 
 
 (53–6.7), CD11c (HL3),
CD11b (M1/70), CD40 (HM40–3), CD45R/B220 (RA3–6B2),
CD86 (GL1), and I-A
 
d
 
/I-E
 
d
 
 (clone 2G9). Biotinylated antibodies
were revealed with PE or PE-Cy5 streptavidin (Dako). For intra-
cellular detection of IL-12p40/p70, cells previously incubated for
2 h in Brefeldin A (Sigma-Aldrich) and stained with CD11c were
processed with the Fix & Perm™ kit (Caltag) and stained with
PE-labeled anti–IL-12 (clone C15.6; BD Biosciences). Parame-
ters were acquired on a FACScan™ (Becton Dickinson).
 
Mixed Leukocyte Reaction.
 
T lymphocytes were obtained
from C57BL/6 (H-2
 
b
 
) mice by depletion of lymph node cells
with anti-CD19, anti-Ia, anti-CD11b, and anti–TER-119 anti-
bodies with anti–rat immunoglobulin magnetic beads (Dynal).
Triplicates of 3 
 
 
 
 10
 
5
 
 purified T cells were incubated with vari-
ous numbers of stimulator cells 
 
 
 
-irradiated (3,000 rad) for 5 d.
Proliferative responses were measured by incorporation of
[
 
3
 
H]thymidine (Amersham Biotech) for the last 18 h of culture.
 
Stimulation of C26-specific CTLs In Vitro.
 
TIDCs enriched
from BALB/c 
 
 
 
 C57BL/6 F1 mice bearing C26 tumors and spleen
DCs from F1 mice were used to stimulate IFN-
 
 
 
 production by the
CTL clone E/88, specific for the murine leukemia virus (MuLV)
 
env
 
-derived AH-1 peptide SPSYVYHQF presented by H-2
 
d
 
, and
the CTL line TG905, specific for the MuLV 
 
env
 
-derived peptide
KSPWFTTL presented by H-2
 
b
 
 as described (9, 17, 18).
 
Cytotoxicity Assay.
 
Spleen cell suspensions were cultured in
the presence of 10
 
5
 
 
 
 
 
-irradiated (20,000 rad) C26 cells and 10
ng/ml IL-2 (Sigma-Aldrich). After 5 d of culture, responder cells
were incubated in a classical 
 
51
 
Cr release-cytotoxic assay with
P815 target cells previously loaded or not with 1 
 
 
 
M AH-1 pep-
tide and labeled with Na
 
51
 
CrO
 
4
 
 (NEN Life Science Products).
Specific cytotoxicity was calculated as: % cytotoxicity 
 
 
 
 100 
 
 
 
(cpm experimental 
 
 
 
 cpm spontaneous release)/(cpm maximum
release 
 
 
 
 cpm spontaneous release).
 
Cytokine Measurements and Numeration of IFN-
 
 
 
–producing Cells
by ELISPOT.
 
Supernatants from the different cultures were col-
lected after 18 h and assayed for IL-12p40, IL-12p70, and TNF
 
 
 
using Duoset
 
® 
 
ELISA antibodies (R&D Systems). ELISPOT 96-
well nitrocellulose-bottom plates (Millipore) coated with rat anti–
mouse IFN-
 
 
 
 (clone R4–6A2; BD Biosciences) were seeded with
2 
 
 
 
 10
 
5
 
 lymph node cells and incubated with 10 ng/ml IL-2 with
or without 1 
 
 
 
M AH-1 peptide for 24 h. IFN-
 
 
 
–producing cells
were revealed by sequential incubations with anti-IFN-
 
 
 
 biotiny-
lated antibody (clone XMG1.2; BD Biosciences), peroxidase-
streptavidin (Southern Biotechnology Associates, Inc.) and sub-
strate (AEC; Vector Laboratories).
 
Statistical Analysis.
 
Statistical analysis of results was performed
with the Statview software (Abacus Concepts). The 
 
 
 
2 
 
test was
used to analyze differences between percentages of tumor bearing
mice at a given time, the log-rank test was used to analyze curves
of tumor development. Student’s 
 
t
 
 test was used in other analyses
when indicated.
 
Results
 
Tumors Are Infiltrated by Immature DCs Refractory to LPS
plus IFN-
 
 
 
 plus Anti-CD40 Stimulation.
 
We isolated
TIDCs from various transplantable tumors as well as from 
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hepatocarcinoma developing in X/
 
myc
 
 transgenic mice
(13) and analyzed their phenotype (Fig. 1). TIDCs purified
from a subcutaneously implanted C26 colon carci-
noma transduced with the 6Ckine chemokine (14) were
CD11b
 
 
 
, CD8
 
 
 
 
 
, and B220
 
 
 
 in their vast majority (Fig. 1
A). As shown previously, this chemokine-induced model
allowed us to recover large numbers of TIDCs, while these
were identical to TIDCs isolated from parental C26 tu-
mors. TIDCs isolated from other transplantable tumors had
also a similar phenotype, thus resembling the classical my-
eloid subset of DCs described in the mouse (19). On the
other hand, TIDCs isolated from liver hepatocarcinoma
were more diverse, including CD11b
 
 
 
 and CD11b
 
 
 
 DCs
as well as cells expressing CD8
 
 
 
 an/or B220, the latter
marker being ascribed to mouse type I IFN-producing cells
(19, 20). We then compared the expression of MHC class II,
CD40, and CD86 molecules of TIDCs to that of lymph node
DCs or immature BM-DCs (Figs. 1 B and 2 A). We observed
that TIDCs had an immature phenotype, with intermediate
levels of surface MHC class II and no detectable CD40 or
CD86 molecules, with the exception of the B16 melanoma
TIDCs which expressed low levels of CD40 and CD86.
A feature of immature DCs is a response to stimulation
with LPS plus IFN-
 
 
 
 plus anti-CD40 antibody by increasing
the expression of CD40 and CD86 (Fig. 2 A) as well as by
producing IL-12 p70 (Fig. 2 B). In contrast, TIDCs from
C26–6CK tumors maintained a similar phenotype under ac-
tivation and did not produce detectable IL-12 p70 (Fig. 2).
Similarly, DCs from normal liver produced IL-12 p70 in re-
sponse to LPS plus IFN-
 
 
 
 plus anti-CD40, whereas TIDCs
from hepatocarcinoma did not (Fig. 2 B). Last, a supernatant
from C26 tumors added at the time of activation abolished
the secretion of IL-12 p70 in BM-DCs (Fig. 2 B). These re-
sults indicate that tumors induced DCs to be refractory to
LPS plus IFN-
 
 
 
 plus anti-CD40 stimulation.
 
Combination of CpG and Anti–IL-10R Antibody Overcomes
TIDCs Paralysis In Vitro.
 
We tested different combina-
tions of substances with the aim of relieving tumor-mediated
inhibition and simultaneously mediating DC activation, in-
cluding combinations of the TLR-9 ligand CpG 1668 (21)
and an anti–IL-10R blocking antibody (15). In control BM-
DCs, CpG alone was able to induce the secretion of IL-
12p70 and TNF
 
 
 
 in amounts similar to that obtained with
LPS plus IFN-
 
 
 
 plus anti-CD40 (Fig. 3 A). The addition of
anti–IL-10R antibody to BM-DC culture increased the pro-
duction of IL-12p70 by 
 
 
 
30% but did not modify TNF
 
 
 
secretion (Fig. 3 A). Of note, we could not detect endoge-
nous production of IL-10 by BM-DCs (detection limit: 15
pg/ml). An anti–IL-10 antibody also increased IL-12p70
production by BM-DCs (unpublished data), suggesting that
indeed IL-10 and not another ligand of IL-10R
 
 
 
 was in-
volved and that low levels of autocrine or paracrine IL-10
were probably sufficient to mediate the effect.
Anti–IL-10R alone was not able to restore significant IL-
12p70 production by TIDC cultured in the presence of LPS
plus IFN-
 
 
 
 plus anti-CD40 (Fig. 3 B), but increased to some
extent their ability to produce TNF
 
 
 
 as well as their capacity
to stimulate allogeneic T cells in MLR (Fig. 3 C). On the
other hand, CpG alone did not induce the secretion of IL-
12p70 nor TNF
 
 
 
 by TIDCs (Fig. 3 B) and minimally im-
proved their function in an MLR (Fig. 3 C). In marked con-
trast, the combination of CpG and anti–IL-10R antibody
induced the secretion by TIDCs of large quantities of IL-
12p70 as well as TNF
 
 
 
 (Fig. 3 B) and was also the best acti-
vation condition for MLR (Fig. 3 C), although we did not
observe a significant increase in CD40 or CD86 expression
after activation (unpublished data). TIDCs produced 0.95 
 
 
 
0.39 ng/ml IL-10 when stimulated with LPS plus IFN-
 
 
 
plus anti-CD40 and 2.36 
 
 
 
 0.62 ng/ml IL-10 when stimu-
lated with CpG. Thus, we identified the combination of
CpG plus anti–IL-10R antibody as a novel and unique way
to activate TIDCs from C26–6CK tumors.
 
CpG 1668 plus Anti–IL-10R Combination Activates TIDCs
In Vivo.
 
We injected C26–6CK tumor-bearing mice with
CpG intratumorally and/or with anti–IL-10R antibody intra-
peritoneally in an attempt to activate TIDCs in vivo (Fig. 4).
We observed that CpG plus anti-IL-10R induced the secre-
tion of intracellular IL-12 p40/70 in a large proportion of
TIDCs as soon as 2 h after treatment, whereas CpG had a
minimal effect and anti–IL-10R alone had no effect.
 
Stimulation of TIDCs with CpG plus Anti–IL-10R Im-
proves TAA-specific Responses In Vivo. To test whether
TIDCs from C26–6CK tumors had been able to capture
and process TAAs in the MHC class I pathway, we ex-
Figure 1. TIDCs may express diverse phenotypes but are immature in
their majority. (A) DCs were enriched from the indicated solid tumors
and analyzed for the expression of CD11c, CD11b, CD8 , and B220 by
flow cytometry (log scale). (B) DCs were enriched from peripheral lymph
node or from the indicated solid tumors and the expression of MHC class
II, CD40, and CD86 molecules was analyzed among gated CD11c  cells
(solid line) compared with isotype control (gray histograms) by flow
cytometry (log scale). Data are representative of two to five experiments.544 CpG plus Anti–IL-10R Reverses Tumor-induced Dendritic Cell Paralysis
amined their capacity to present TAA-derived peptides
to CTL, as described previously for a C26 tumor engi-
neered to express GM-CSF and CD40L (9; Fig. 5 A).
The C26 (H-2d) colon carcinoma expresses an immu-
nodominant TAA which contains the Ld-restricted pep-
tide AH-1 (18), recognized by the E/88 CTL clone.
The MC38 (H-2b) colon carcinoma expresses the same
TAA and contains a Kb-restricted peptide recognized by
the TG905 CTL line (17). Stimulation of E/88 or
TG905 cells by C26 and MC38 cells, respectively, in-
duced IFN-  production in an MHC-restricted fashion
(Fig. 5A). TIDCs purified from BALB/c   C57BL/6
(H-2dxb) F1 mice bearing C26–6CK tumors were able to
stimulate both CTL lines in a cell dose-dependent fash-
ion, whereas spleen DCs purified from naive H-2dxb F1
mice stimulated IFN-  production only when pulsed
with the relevant peptide (Fig. 5 A). In particular, the
stimulation of the H-2b TG905 CTL clearly indicates
that TIDCs have been able to capture and present exog-
enous TAA in the MHC class I pathway.
Figure 2.  TIDCs are not activated by LPS plus IFN-  plus anti-CD40 stimulation. (A) Control BM-DCs or enriched C26–6CK TIDCs were cultured
overnight with medium alone or with the combination of LPS, IFN-  plus anti-CD40 antagonist antibody. Flow cytometry histograms (log scale) show
the expression of MHC class II, CD40, and CD86 among gated CD11c  cells (solid lines) in unstimulated (top panels) or stimulated (bottom panels) DC
populations. The percentage of positive cells was determined by comparison with isotype control (gray histogram) and is indicated in the top right corner
of each histogram. Results are representative of more than five experiments. (B) The ability to respond to LPS plus IFN-  and anti-CD40 activation was
analyzed by measuring IL-12p70 levels in 18 h culture supernatants in various DC populations: DCs isolated from C26–6CK tumors or axillary draining
lymph nodes from the same tumor-bearing animals; DCs enriched from hepatocarcinoma developing in x/myc transgenic mice or from normal liver;
BM-DCs cultured in the presence or absence of supernatant from C26 tumors. ELISA results are expressed as the mean concentration   SEM of triplicate
cultures. Similar results were obtained in two to five experiments, depending upon the conditions tested.
Figure 3. Combination of CpG 1668 and anti–IL-10R antibody over-
come TIDC paralysis in vitro. (A and B) BM-DCs and TIDCs enriched from
C26–6CK tumors were activated overnight with either LPS, IFN- , and
anti-CD40 (white bars), or CpG 1668 (black bars) in the presence (anti–IL-
10R) or absence (none) of anti–IL-10R antibody. Culture supernatants were
assayed for IL-12p70 and TNF  content. Results are expressed as the mean
concentration   SEM of triplicate cultures and are representative of more
than three experiments. (C) Mixed leukocyte reaction. Irradiated populations
of enriched TIDCs, previously activated overnight with none ( ), CpG
1668 ( ), CpG plus anti–IL-10R ( ), LPS plus IFN-  plus anti-CD40 ( ),
or anti–IL-10R plus LPS plus IFN-  plus anti-CD40 ( ), were cultured
with allogeneic purified T cells. Proliferation is expressed as the mean cpm
incorporation   SEM for triplicates.545 Vicari et al.
We then analyzed the capacity of TIDCs from C26–
6CK tumors to induce TAA-specific responses in vivo
(Fig. 5, B and C). After enrichment and overnight activa-
tion, we injected TIDC to naive mice and 5 d later we
measured the AH1-specific response. We found that TIDC
from C26–6CK tumors were able to induce AH-1-specific
cytotoxicity (Fig. 5 B) as reported previously for C26-GM-
CD40L tumors (9). Activation of TIDCs with CpG plus
anti–IL-10R did not significantly increase the AH-1–spe-
cific cytotoxicity (Fig. 5 B). We observed, however, that
only TIDCs activated with CpG plus anti–IL-10R were
able to induce significant numbers of AH-1–specific IFN-
 –producing cells (Fig. 5 C). The number of non-AH-1
specific IFN- –producing cells was also increased over
controls, and we ascribed this data to the fact that the T cell
activation triggered by the injection of CpG plus anti–IL-
10R-activated TIDCs 5 d before might still be present and
include AH-1–specific as well as nonspecific effector cells.
Collectively, these results strongly suggest that activation
with CpG plus anti–IL-10R antibody increases TAA-spe-
cific immune responses.
The Refractory State of TIDC to LPS plus IFN-  plus Anti-
CD40 Activation and Their Sensitivity to CpG plus Anti–IL-
10R Are Not Restricted to C26–6CK Tumors. We ana-
lyzed CD11c and IL-12 p40/p70 intracellular expression
after overnight activation with either LPS plus IFN-  plus
anti-CD40 or CpG plus anti–IL-10R in TIDCs enriched
from C26, B16F0, LL2, and TSA transplantable tumors as
well as from X/myc hepatocarcinoma (Fig. 6 A). As for
C26–6CK TIDCs, DCs isolated from these tumors did not
respond to LPS plus IFN-  plus anti-CD40 but showed a
robust response to CpG plus anti–IL-10R (Fig. 6 A). Iden-
tical results were obtained by measuring IL-12p70 levels in
culture supernatants, albeit we detected minimal IL-12p70
secretion by B16F0 melanoma TIDCs activated with LPS
plus IFN-  plus anti-CD40 (Fig. 6 B). Thus, the refractory
state of TIDCs to LPS plus IFN-  plus anti-CD40 activa-
tion and their sensitivity to CpG plus anti–IL-10R can be
observed in tumors from different histological origin as
well as in a transgenic tumor model.
Combination of CpG and Anti–IL-10R Antibody Has
Therapeutic Antitumor Effect In Vivo. We treated mice im-
planted with subcutaneous C26 or B16F0 tumors with
various combinations of CpG 1668, control GL113 anti-
body, or anti–IL-10R antibody (Fig. 7, A and B). We
Figure 4. CpG 1668 plus anti–IL-10R activates tumor-infiltrating DCs
in vivo. Mice bearing C26–6CK tumors were injected intratumorally
with 5  g CpG 1668 or control GpG sequence and/or intraperitoneally
with 250  g anti–IL-10R or isotype control antibody. 2 h after injection,
mice were killed, and TIDCs enriched and stained for intracellular IL-12
p40/p70 and surface CD11c. The percentage of IL-12–positive cells
among CD11c-enriched TIDCs was determined by comparison with
isotype control and is indicated in the top right corner.
Figure 5. Induction of tumor antigen–specific immune responses by
TIDCs and modulation by CpG plus anti–IL-10R. (A) TIDC cross-
present tumor antigen–derived peptides to T cells. The ability of TIDCs
from C26–6CK tumors grown in H-2d   H-2b F1 mice to present tumor-
derived antigenic peptides was assessed by measuring the secretion of
IFN-  by the CTL clone E/88 (H-2d CTL, white bars) and CTL cell
line TG905 (H-2b CTL, black bars). Positive controls consisted of DCs
enriched from H-2d   H-2b spleens (APC) and pulsed with the relevant
peptide(s) as well as MCA38 H-2b and C26 H-2d cell lines which both
express the antigen. (B and C) TIDCs stimulated with CpG 1668 plus
anti–IL-10R induce tumor-associated antigen MHC class I–restricted
responses in vivo. TIDCs enriched from C26–6CK tumors were cultured
overnight with medium alone (TIDC) or CpG 1668 plus anti–IL-10R
antibody (TIDC   CpG   a-IL10R), then injected intracutaneously into
naive mice. Controls consisted of uninjected mice (negative control) or
mice injected with irradiated C26 cells (irrad. C26). Mice were killed 5 d
after injection. Experiments were performed with organs pooled from
three naive mice and similar results obtained in two separate experiments.
(B) Spleens from injected animals were cultured with irradiated C26 cells
and IL-2 and cytotoxicity measured against P815 H-2d target cells, alone
(white bars) or loaded with the AH-1 antigenic peptide of C26 (black
bars). Results are expressed as the mean cytotoxicity   SEM per triplicate
wells at an effector/target ratio of 1:100. (C) Total cell suspensions from
pooled draining popliteal lymph nodes were analyzed for IFN- –producing
cells after overnight culture without (white bar) or with (black bar) AH-1
peptide. Results are expressed as the mean number of spots   SD for
six different wells.546 CpG plus Anti–IL-10R Reverses Tumor-induced Dendritic Cell Paralysis
observed that anti–IL-10R or CpG alone had no effect
on tumor incidence or survival in the C26 model, nor
on tumor incidence in the B16F0 model (Fig. 7, A and
B). Treatment with CpG alone had a weak effect on
survival in the B16F0 model (Fig. 7 B). In marked con-
trast, combination of CpG plus anti–IL-10R had a sig-
nificant effect on tumor incidence (P   0.01 for C26
and P   0.05 for B16F0 compared with control by  2
test) and on survival (P   0.002 for C26 and P   0.006
for B16F0 by logrank analysis) in both models (Fig. 7, A
and B). We also found similar results in a model where
C26–6CK tumors were implanted (unpublished data).
Of note, most of the mice treated with CpG plus anti–
IL-10R did show palpable tumors, but many developed
local necrosis and eventually rejected the tumor.
Therapeutic Effect of CpG plus Anti–IL-10R Depends on In-
nate and Adaptive Immune Effector Cells. In several addi-
tional groups of C26 tumor-bearing mice inoculated
with C26 tumor cells and treated with anti–IL-10R plus
CpG, we injected antibodies in order to deplete CD4 
or CD8  cells or NK cell activity (Fig. 8 A). Although
CpG plus anti–IL-10R antibody induced some level of
tumor rejection in depleted groups, the combination
was less efficient than in nondepleted groups. All mice
which rejected the tumor remain tumor-free for the rest
of the experiments while those which developed tumors
were killed between 4 to 6 wk for antibody-depleted
groups and 3 to 5 wk for SCID mice. These data suggest
that several components of the adaptive and innate im-
mune response, including CD4 , CD8  T cells, and NK
cells, might contribute to tumor eradication. We also
treated C26 tumor-bearing SCID mice, which lack T
Figure 6. DCs from various transplantable
or transgene-induced tumors are refractory
to activation with LPS, IFN-  plus anti-
CD40 but not with CpG 1668 plus anti–IL-
10R. The ability of TIDC populations
enriched from the indicated tumors to
produce IL-12 in response to LPS plus
IFN-  and anti-CD40 or CpG 1668 plus
anti–IL-10R was analyzed: (A) by intracellular
staining for IL-12p40/p70 together with
surface CD11c staining (log scale), percentages
of CD11c  cells expressing intracellular
IL-12 are indicated in the top right quadrant;
(B) by measuring IL-12 p70 levels in TIDC
culture supernatant by ELISA. Results (log
scale) are expressed as the mean concentra-
tion   SEM from triplicate cultures.
Figure 7. Treatment with CpG 1668 plus anti–IL-10R induces tumor
rejection. Groups of seven mice were injected subcutaneously at day 0
with 5   104 C26 (A) or B16F0 (B) tumor cells. Mice were treated at day
7, 14, and 21 (arrows) with control antibody, 5  g CpG 1668 injected
intratumorally, 250  g anti–IL-10R antibody intraperitoneally, or CpG
plus anti–IL-10R. Tumor incidence and survival were monitored in all
groups for the indicated times.547 Vicari et al.
and B cells (Fig. 8 B). There was no significant impact of
the treatment on tumor incidence and survival, strongly
suggesting a role for T cell and perhaps B cells in the
therapeutic effect of CpG plus anti–IL-10R in immuno-
competent mice.
Therapeutic Effect of CpG plus Anti–IL-10R Can Be the
Result of TIDC Activation and Results in Immune Memory.
Local treatment with CpG and systemic treatment with
anti–IL-10R antibody could have an effect outside of the
tumor or act on tumor-infiltrating cells different from DCs.
To analyze the direct contribution of activated TIDCs to
the antitumor effect, we purified TIDC from C26–6CK
tumors, activated them in vitro for 2 h, and then reinjected
them intratumorally into C26 tumor-bearing mice (Fig. 8
C). The mice were additionally treated with intraperitoneal
injections of anti–IL-10R antibody. We observed a signifi-
cant increase in survival (P   0.03 by logrank analysis) in
mice injected by TIDCs activated with CpG plus anti–IL-
10R compared with TIDCs activated with LPS plus IFN- 
plus anti-CD40 plus anti–IL-10R or resting TIDCs (Fig. 8
C). This result suggests that CpG plus anti–IL-10R can
promote DC-mediated antitumor effect.
Last, we analyzed the anti-tumor immune memory re-
sponse in mice cured of C26 tumors with CpG plus anti–
IL-10R treatment by rechallenging the animals with C26
cells, 45 d after the first challenge (Fig. 8 D). We observed
that only 25% of the mice developed tumors, and with a
marked delay when compared with naive mice, suggesting
the establishment of an anti-tumor immune memory re-
sponse after CpG plus anti–IL-10R therapy.
Discussion
Impaired DC functions could explain poor immune re-
activity against tumors (for a review, see reference 12). The
presence of refractory TAA-loaded immature dendritic
cells within tumors could lead not only to the absence of an
efficient antitumor response but also to the induction of a
tolerogenic response. Indeed, it was recently reported that
immature DC injection would induce antigen-specific T
cell unresponsiveness in man (22). It was also shown that
IL-10 expressed within tumors could promote the genera-
tion of tolerogenic regulatory T cells (23). Thus, finding
pharmacological means to properly induce TIDC activa-
tion could define a novel strategy to cure cancer.
We first observed that DCs from transplantable tumors
had an uniform phenotype of classical CD8  CD11b  my-
eloid DCs (19). TIDCs from C26–6CK tumors did not ei-
ther express CD205 or CD4 (unpublished data), although
lack of CD4 expression could have resulted from in situ
down-regulation, a phenomenon we observed in tumor-
infiltrating CD4 T cells (unpublished data). In contrast, TIDCs
from X/myc hepatocarcinoma were representative of distinct
subsets of mouse DCs (19). It is therefore possible that trans-
plantable tumors are biased in their recruitment of TIDCs.
Nonetheless, as we observed that TIDCs from X/myc hepa-
tocarcinoma or normal bone marrow or spleen DCs cultured
in the presence of tumor supernatant were functionally in-
hibited (Fig. 2, and unpublished data), we do not think that
the TIDC refractory state we describe herein is restricted to a
particular subset of DCs. The inability of TIDCs to respond
to LPS could not be ascribed to a lack of TLR4 mRNA ex-
Figure 8. Treatment with CpG 1668 plus anti–IL-10R induces T cell
and NK cell–mediated tumor rejection as well as antitumor immune
memory. Groups of seven mice were injected subcutaneously at day 0
with 5   104 C26 tumor cells. (A) Mice were treated at day 7, 14, and 21
(arrows) with control or 5  g CpG 1668 injected intratumorally plus 250
 g anti–IL-10R antibody intraperitoneally. Indicated groups of mice
receiving anti–IL-10R plus CpG were further treated with anti-CD4,
anti-CD8, or Asialo-GM1 depleting antibodies as described in Materials
and Methods. (B) Immunodeficient SCID mice were treated at day 7, 14,
and 21 (arrows) with control, 5  g CpG 1668 injected intratumorally,
250   g anti–IL-10R antibody intraperitoneally or CpG plus anti–IL-
10R. (C) Mice were injected intratumorally at day 7, 14, and 21 (arrows)
with 5   104 enriched tumor-infiltrating DCs activated for 2 h in vitro
with none, LPS plus anti-CD40 plus anti–IL-10R, or CpG plus anti–IL-
10R, as well as intraperitoneally with 250  g anti–IL-10R antibody. (D)
Mice treated with CpG plus anti–IL-10R that had rejected a C26 tumor
inoculated at day 0 (n   12) were rechallenged at day 45 with 5   104
C26 cells in the contralateral flank and compared naive mice challenged
with the same inoculum. Tumor incidence and survival were monitored
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pression (unpublished data). To some extent, TIDCs were
not completely refractory either to CD40-mediated or to
IFN- -R signaling, as anti-CD40 antibody as well as IFN- 
further increased IL-12p70 secretion in response to CpG
plus anti–IL-10R (unpublished data).
We found that the refractory state of TIDCs was likely
induced by soluble tumor-derived factor(s), as supernatant
fluid from C26 tumors could similarly paralyze BM-DCs.
The ability to induce TIDC activation with the combina-
tion of anti–IL-10R plus CpG, as well as with an anti–IL-
10 antibody plus CpG (unpublished data), strongly suggests
that IL-10 was one of the factors responsible for the induc-
tion of the refractory state in vivo, as already described for
tumor-associated macrophages (24). Indeed, the C26 tu-
mor supernatant used in the present study contained 240
pg/ml IL-10, as measured by ELISA. Of note, TIDCs
from our tumor models did not respond to CpG alone ei-
ther, in contrast with regular DCs. It was only when anti–
IL-10R was added that CpG induced a strong activation of
TIDCs. Therefore, as already shown by our previous re-
port (15), it seems that anti–IL-10R antibody can strongly
potentiate a microbial stimulus, in particular mediated
through a Toll-like receptor. It that particular case, it over-
came the unresponsiveness resulting from soluble antigen
administration (15). Moreover, it is possible that some
pathways of activation downstream of TLRs are com-
pletely shut down in TIDCs while others are still opera-
tive, as CpG but not LPS was efficient in combination
with anti–IL-10R. Other observations have already sup-
ported divergent activation pathways via TLR4 and TLR9
(25, 26). The study of TLR-related activation pathways
still operative in TIDCs could define novel targets for can-
cer therapy. Furthermore, it will be of important to test
whether our observations also apply to human tumor-infil-
trating DCs. Interestingly, a population of plasmacytoid
DC precursors has recently been described in human ova-
rian cancer (27) and these cells, in normal individuals, ex-
press TLR9 and respond to selected CpGs (28). Thus, it
would be extremely relevant to examine TIDC response to
CpG sequences in human TIDCs.
We last found that the CpG plus anti–IL-10R combina-
tion had a potent therapeutic anti-tumor effect and induced
immune memory. CpG immunostimulatory sequences had
been shown to be a potent adjuvant of antitumor immune
responses, primarily when mixed with a source of TAA
(29–31). Repeated high-dose peritumoral or intraperito-
neal injection of CpG could also lead to tumor rejection in
the B16 model (32, 33). We found, however, that the
combination of CpG plus anti–IL-10R was far more effec-
tive than CpG alone. Direct injection of ex vivo activated
DCs also had an antitumor effect, albeit to a lesser extent,
suggesting that activated TIDCs is a major component of
CpG plus anti–IL-10R therapy. The better effect of CpG
plus anti–IL-10R therapy when compared with intratu-
moral TIDC reinfusion could be related to the additional
activation of extratumoral DCs. In addition, DCs injected
intratumorally may not find the proper way to migrate
and/or exert their beneficial effect in situ. When we in-
jected labeled DCs into the tumor and try to recover them
the day after, we found very few cells either in the tumor
or in the draining lymph node or spleen, suggesting an im-
portant cell death during the procedure (unpublished data).
In conclusion, our data suggest that using a microbial stim-
ulus by itself may not be effective in some cancers, if DCs
that are normally responding to it become refractory be-
cause of tumor-derived factors. We postulate that using an-
tagonists of tumor inhibitory factors such as anti–IL-10R
may significantly lower the threshold required for TIDC
activation to a point amenable for successful immunother-
apy using biological modifiers such as CpG sequences.
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